Kestra Advisory Services, LLC Cyclacel Pharmaceuticals, Inc. Transaction History

Kestra Advisory Services, LLC

  • $17.6 Billion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 01, 2022
BUY
$1.23 - $21.9 $28,290 - $503,699
23,000 New
23,000 $34 Million

About Cyclacel Pharmaceuticals, Inc.

CYCC Quotes by TradingView
  • Ticker CYCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,539,200
  • Market Cap $7.9M
  • Description
  • Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...
More about CYCC
Track This Portfolio

Track Kestra Advisory Services, LLC Portfolio

Follow Kestra Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kestra Advisory Services, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email